ESMO 2025: vídeos e entrevistas
195 vídeos do ESMO 2025 publicados por ESMO, OncLive, Oncology Brothers, VJOncology, ecancer. Atualizado em 20/11/2026.
Tarlatamab plus chemo-IO shows promising efficacy in extensive-stage SCLCecancer · 15/05/2026 · 6:31 · apoio da indústria
177Lu-PSMA-617 with androgen deprivation therapy plus ARPI improves PFS for mHSPCecancer · 15/05/2026 · 6:00 · apoio da indústria
ctDNA-guided adjuvant chemo de-escalation reduces toxicity with comparable outcomes in stage III...ecancer · 16/02/2026 · 7:19 · apoio da indústria
ESMO 2025: Prostate highlightsecancer · 16/02/2026 · 6:26 · apoio da indústria
ESMO 2025: Bladder cancer highlightsecancer · 16/02/2026 · 4:21 · apoio da indústria
ESMO 2025: Renal highlightsecancer · 16/02/2026 · 3:56 · apoio da indústria
The future of bispecific checkpoint inhibitors for solid tumorsVJOncology · 10/02/2026 · 1:19 · apoio da indústria
What are the advantages of co-targeting of LAG-3 and PD-1 in oncology?VJOncology · 10/02/2026 · 1:32 · apoio da indústria
First-in-human study of INCA32459, a LAG-3/PD-1 bsAb in advanced cancersVJOncology · 10/02/2026 · 2:50 · apoio da indústria
Trastuzumab deruxtecan improves disease-free survival vs trastuzumab emtansine in high-risk HER2...ecancer · 05/02/2026 · 12:49 · apoio da indústria
Perioperative enfortumab vedotin plus pembro improves survival and pCR in cisplatin-ineligible MIBCecancer · 05/02/2026 · 4:18 · apoio da indústria
ctDNA-guided adjuvant atezolizumab improves OS in MIBCecancer · 05/02/2026 · 3:24 · apoio da indústria
MCED blood test demonstrates high specificity, strong predictive value, and increased early canc...ecancer · 05/02/2026 · 5:32 · apoio da indústria
Tarlatamab shows manageable safety profile with fewer toxicities than chemo in 2L SCLCecancer · 05/02/2026 · 5:10 · apoio da indústria
Giredestrant plus everolimus new treatment option in ER+, HER2– advanced breast cancer, post-CDK...ecancer · 05/02/2026 · 4:21 · apoio da indústria
Circulating tumour DNA a useful marker in CRC treatment efficacy, but only alongside othersecancer · 05/02/2026 · 5:11 · apoio da indústria
Taletrectinib shows efficacy and tolerability in advanced ROS1+ NSCLC previously treated with en...ecancer · 05/02/2026 · 4:55 · apoio da indústria
The upcoming role of ADCs and immunotherapy in bladder cancer in 2026VJOncology · 15/01/2026 · 1:03 · apoio da indústria
Real-world outcomes with S-1 in advanced cutaneous squamous cell carcinomaVJOncology · 14/01/2026 · 1:53 · apoio da indústria
Novel strategies targeting c-Met in non-small cell lung cancerVJOncology · 14/01/2026 · 6:03 · apoio da indústria
Advancements and regional trends in CAR-T cell therapy clinical trialsVJOncology · 14/01/2026 · 1:53 · apoio da indústria
Assessing precemtabart tocentecan for CRC in the PROCEADE-CRC-01 trialVJOncology · 14/01/2026 · 5:57 · apoio da indústria
Single-port surgery advances for mediastinal tumor resectionVJOncology · 14/01/2026 · 3:33 · apoio da indústria
ARTEMIDE-HCC01: first-line rilvegostomig plus bevacizumab in uHCCVJOncology · 13/01/2026 · 2:09 · apoio da indústria
Multidisciplinary team maturity and gaps in hepatocellular carcinoma careVJOncology · 13/01/2026 · 1:28 · apoio da indústria
Increasing eligibility for surgery with neoadjuvant therapy in lung cancerVJOncology · 13/01/2026 · 1:05 · apoio da indústria
How can clinicians incorporate peri-operative treatment in lung cancer?VJOncology · 13/01/2026 · 1:13 · apoio da indústria
Biomarkers guiding treatment selection in endometrial cancerVJOncology · 13/01/2026 · 2:10 · apoio da indústria
The future targeted therapies and ADCs in metastatic endometrial cancerVJOncology · 13/01/2026 · 3:46 · apoio da indústria
Treatment strategies for non-dMMR advanced metastatic endometrial cancerVJOncology · 13/01/2026 · 2:48 · apoio da indústria
MTAP loss as a prognostic and immunologic marker across solid tumorsVJOncology · 13/01/2026 · 6:23 · apoio da indústria
Upgrading the efficacy of ECOG performance status in ovarian cancerVJOncology · 12/01/2026 · 3:41 · apoio da indústria
Progression-free status at 6 months as a prognostic marker in PROCVJOncology · 12/01/2026 · 3:10 · apoio da indústria
How can we move beyond endocrine therapy in HR+/HER2- breast cancer?VJOncology · 12/01/2026 · 4:44 · apoio da indústria
TROPION-Breast02: first-line datopotamab deruxtecan in metastatic TNBCVJOncology · 12/01/2026 · 7:05 · apoio da indústria
2026 updates and upcoming trials in prostate cancer radiotherapyVJOncology · 07/01/2026 · 1:41 · apoio da indústria
PACE-C: two-year toxicity outcomes with SBRT versus MHRT in prostate cancerVJOncology · 07/01/2026 · 1:12 · apoio da indústria
The emerging role of TKI-immunotherapy combinations in solid tumorsVJOncology · 07/01/2026 · 1:39 · apoio da indústria
How can RNA profiling further enhance precision oncology?VJOncology · 07/01/2026 · 2:37 · apoio da indústria
mRNA expression as a predictor of TKI efficacy in advanced solid tumorsVJOncology · 07/01/2026 · 1:45 · apoio da indústria
Updates in biomarker-based approach in hepatobiliary & pancreatic cancersVJOncology · 05/01/2026 · 3:04 · apoio da indústria
DEBATE: neoadjuvant durvalumab and chemotherapy in localized BTCVJOncology · 05/01/2026 · 3:06 · apoio da indústria
TOURMALINE: durvalumab and gemcitabine-based chemotherapy in BTCVJOncology · 05/01/2026 · 2:37 · apoio da indústria
ctDNA MRD guides adjuvant therapy in resected hepatocellular carcinomaVJOncology · 05/01/2026 · 2:01 · apoio da indústria
177Lu-DOTATATE improves outcomes in advanced GEP-NETs versus octreotideVJOncology · 05/01/2026 · 2:05 · apoio da indústria
Updated efficacy and biomarkers of QL1706, a PD-1/CTLA-4 dual blockerVJOncology · 24/12/2025 · 8:22 · apoio da indústria
Phase I study of APG-2449 in advanced ALK+ and ROS1+ NSCLCVJOncology · 24/12/2025 · 6:19 · apoio da indústria
Phase I trial of BPB-101, a GARP/TGF-β/PD-L1 bispecific ADC in solid tumorsVJOncology · 24/12/2025 · 3:45 · apoio da indústria
Challenges and strategies for off-the-shelf allogenic CAR T-cell therapiesVJOncology · 24/12/2025 · 1:53 · apoio da indústria
The current state of cellular therapies in the Asia-Pacific regionVJOncology · 24/12/2025 · 1:46 · apoio da indústria
Highlighting the role of HPV vaccines in precenting HPV-associated cancersVJOncology · 18/12/2025 · 1:13 · apoio da indústria
Overcoming PD-1-resistance in head and neck cancer with ADCs and bsAbsVJOncology · 18/12/2025 · 5:21 · apoio da indústria
Monitoring ADC and checkpoint inhibitor-related toxicity in oncologyVJOncology · 18/12/2025 · 1:08 · apoio da indústria
How are ADC and ICI combinations redefining breast cancer treatment?VJOncology · 18/12/2025 · 4:22 · apoio da indústria
The emerging role of ADC and checkpoint inhibitor combinations in UCVJOncology · 18/12/2025 · 1:56 · apoio da indústria
Multi-specific antibodies to overcome limits of cancer immunotherapyVJOncology · 18/12/2025 · 2:04 · apoio da indústria
Spatial T-cell communities and their impact on immunotherapy responseVJOncology · 18/12/2025 · 1:54 · apoio da indústria
What to look our for in melanoma treatment in 2026VJOncology · 18/12/2025 · 1:10 · apoio da indústria
Expanding biomarkers beyond PD-L1 and TMB in melanomaVJOncology · 18/12/2025 · 1:18 · apoio da indústria
What are the benefits of armed oncolytic viruses over unmodified viruses?VJOncology · 18/12/2025 · 2:58 · apoio da indústria